All News
Sleep Apnea Smart Watches (10.13.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
Read Article
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw
Dr. John Cush RheumNow ( View Tweet)
Full Read review of #PMR in Lancet:
- Start @ 12·5–25mg prednisone qd
- Remission in most but, relapses in 40–60%
- Onset sudden; AM stiffness predominates; Shoulders>Pelvic
~50% have distal MSK Sxs
- US: look for B/L sub-acromial/deltoid bursitis https://t.co/0j1nRmdizP https://t.co/7cURm1pQeB
Links:
Dr. John Cush RheumNow ( View Tweet)
#PMR: glad or bad tidings?
Please don’t tell your patient that PMR “typically” lasts two years. Because it probably won’t last exactly two years, and then they’ll be less inclined to believe other things you say.
Read more...
https://t.co/UXuUzEVjFI
@sarah_L_mackie https://t.co/UnXsyuq4V4
Dr. John Cush RheumNow ( View Tweet)
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/6ZxIcHbUEd https://t.co/Cx0kbn7JU2
Dr. John Cush RheumNow ( View Tweet)
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
Dr. John Cush RheumNow ( View Tweet)
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/c4mYjdLKW7 https://t.co/lXh5klx0cq
Dr. John Cush RheumNow ( View Tweet)
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j
Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zjXyldwlyl https://t.co/CpQ00745c1
Links:
Dr. John Cush RheumNow ( View Tweet)
#PMR: Is There Hidden GCA?
Dr. Anisha Dua, asks the question: in PMR should you worry about occult GCA?
https://t.co/Cd6u2GwJuo
@anisha_dua https://t.co/dWUH4zudPc
Links:
Dr. John Cush RheumNow ( View Tweet)
UK researchers develop a human vascularised synovium-on-a-chip: mechanically stimulated, 3D, microfluidic device w/ synovial cells and blood vessel cells to investigate syn inflammation & monocyte recruitment, mimics the forces applied w/ joint movement https://t.co/qlRHSE3o2b https://t.co/dsKvcsyysa
Dr. John Cush RheumNow ( View Tweet)
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/q6aqtcaTxS https://t.co/uZSgoYuxJT
Dr. John Cush RheumNow ( View Tweet)
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation? QD Clinics are video vignettes with lessons from the clinic.
https://t.co/YhTkKpmzIl
@sattuiSEMD https://t.co/FTsz3QA5Cn
Dr. John Cush RheumNow ( View Tweet)
IL-6 Inhibitors in #PMR: Give early or late?
https://t.co/tMdriuFPYB https://t.co/WMhuogIMJC
Dr. John Cush RheumNow ( View Tweet)
Draw Your Arthralgias
Featuring Dr. David Liew (Melbourne, Australia)
54 yr old with polyarthralgias, & slightly abnormal labs; could this be #PMR?
https://t.co/siP6Kv1Z1X https://t.co/cMy5ZTybUn
Dr. John Cush RheumNow ( View Tweet)
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/yt2GtawuDp https://t.co/FUMFnIXFkk
Dr. John Cush RheumNow ( View Tweet)
Surprising Link Between Weight Gain and RA Activity
In patients with RA treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.
https://t.co/hXuJbwiY7B https://t.co/G88CTkSlB5
Dr. John Cush RheumNow ( View Tweet)
Importance of Diagnostic Imaging in #PMR
Dr. Claire Owen, Melbourne, discusses the importance of imaging to the diagnosis of polymyalgia rheumatica. This is part of a video series produced by RheumNow for its October 2023 campaign, Make Rheum for PMR.
https://t.co/IZAlfcjWDX https://t.co/B5rvy1J140
Dr. John Cush RheumNow ( View Tweet)
Felson reports a novel model to study knee OA. 2,340 Adults from the MOON study undergoing post-traumatic ACL reconstructions (ACLR), 16-26% identified w/ continued w/ knee pain & at risk for accelerated #OA -->study of interventions https://t.co/rDaNmeCGXM https://t.co/tm0kZ2ax78
Dr. John Cush RheumNow ( View Tweet)
In 2024, the new Samsung Galaxy watch will be able to detect sleep apnea using the Samsung Health Monitor app that monitors BP, ECG, irregular heart rhythm, and blood O2 levels. Approved by Korea’s Ministry of Food and Drug Safety for use in Korea. https://t.co/ijWNzYWiF5 https://t.co/2nRkgzuYfI
Dr. John Cush RheumNow ( View Tweet)